PHIOHealthcare · BiotechnologyPHIO Stock Forecast: Phio Pharmaceuticals Corp. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Phio Pharmaceuticals Corp. hold a median 12-month price target of $14 — +1259.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
PHIO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Phio Pharmaceuticals Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Value (11): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Phio Pharmaceuticals Corp. — and when they’d sell — is the membership.
PHIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PHIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1259.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | $14 |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2025 | HC Wainwright & Co. | Assumes | Buy | $14 |
| 8 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Feb 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 June 2021 | HC Wainwright & Co. | Maintains | Buy | $4.00 → $6.00 |
| 25 Nov 2020 | HC Wainwright & Co. | Initiates | Buy | — |
| 5 Aug 2020 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PHIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Phio Pharmaceuticals Corp. (PHIO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- 0.4×
Cheaper than 74% of US stocks
Cheaper than 79% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −76.4%
- Return on assets
- −46.7%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PHIO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHIO appears on the weeks it earns a place.
Frequently asked questions about PHIO stock
What is the PHIO stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Phio Pharmaceuticals Corp. have a median 12-month price target of $14, with estimates ranging from $14 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PHIO stock a buy right now?
Of the 1 analysts covering Phio Pharmaceuticals Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phio Pharmaceuticals Corp. 22 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PHIO?
As at 1 Aug 2026, Phio Pharmaceuticals Corp. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
Will PHIO stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1259.2% from the last close, and Ticker Nerd's factor model ranks Phio Pharmaceuticals Corp. 22 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PHIO stock forecast for 2030?
No analyst covering Phio Pharmaceuticals Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $14 over the next 12 months.
How has PHIO stock performed over the past year?
Phio Pharmaceuticals Corp. returned -55.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Phio Pharmaceuticals Corp. do?
Phio Pharmaceuticals Corp. is a biotechnology company focused on developing immuno-oncology therapeutics aimed at treating cancer.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. is a biotechnology company focused on developing immuno-oncology therapeutics aimed at treating cancer. The company's primary goal is to leverage its proprietary self-delivering RNAi (sd-rxRNA) technology, designed to advance immune responses against cancer by enhancing the activation and persistence of immune cells. This innovative platform is central to its efforts in creating treatments that improve the efficacy of existing cancer therapies or standalone applications. Phio Pharmaceuticals Corp. is actively engaged in research and development, and its initiatives predominantly impact the biotechnology and healthcare sectors. Based in Marlborough, Massachusetts, the company plays a significant role in the ongoing efforts to find novel solutions to combat challenging cancer types, positioning itself as a key player in immunotherapy advancements. By collaborating with other biotech firms and healthcare institutions, Phio Pharmaceuticals aims to bring effective, trailblazing medicines to market, which could significantly alter the landscape of cancer treatment.
CEO Mr. Robert J. Bitterman · 6 employees · United States · https://phiopharma.com